Search Results - mabs

4 Results

Sort By:

Cancer Therapies Using Engineered Monomeric Fc Molecules

Abstract: The National Cancer Institute, Nanobiology Program seeks parties interested in collaborative research to co-develop engineered molecules therapies. Efforts to engineer antibody-based therapeutics, to date, have encountered technical limitations due to the relatively large fragment size and short fragment half-life. Antibody fragments are emerging...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Tianlei Ying

Keywords(s): FcRn, IgG1, mabs, MFC, neonatal Fc receptor

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains

The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER)...

Published: 7/25/2024 | Inventor(s): John Mascola, Leo Laub, Jinghe Huang, Peter Kwong, Gilad Ofek, Jiang Zhu, Gary Nabel, Ivelin Georgiev, Yongping Yang, Rebecca Rudicell, Mark Connors

Keywords(s): antibodies, ANTIBODY, ANTI-HIV, Anti-HIV-1, Anti-HIV-l, Broadly Neutralizing Antibody, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, gp41, Human, ISOLATING, Knowledge, mabs, Membrane-Proximal, Method, monoclonal, Neutralizing, prior, Producing, Specificity, VLXXXX, WITHOUT, WJXXXX, XAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, ResearchProducts > Antibodies, Application > Therapeutics, Application > Vaccines

HIV Monoclonal Antibodies

This technology describes several hybridomas that produce monoclonal antibodies (mAbs) useful in HIV research applications. The mAbs are specific for either gp41 or gp120. In particular, the hybridomas producing mAbs designated D19, D56, M12, T8 and T24 (all anti-gp120), and T32 and T33 (gp41 specific) were found to be of particular utility. Additional...

Published: 7/25/2024 | Inventor(s): Patricia Earl, Christopher Broder, Robert Doms, Bernard Moss

Keywords(s): 597-613, Anti-gp41, DDXXXX, DXXXXX, mabs, T32, T33, T40, VLXXXX, WIXXXX

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, TherapeuticArea > Infectious Disease

Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin Type A

Two chimpanzee mAbs specifically reacted with light chain of the botulinum neurotoxin A and neutralize the toxin in the mouse model. They can be used for emergency prophylaxis and treatment of either naturally acquired or terrorist associated botulism. Since the sequence of chimpanzee immune globulin is virtually identical to that of humans, the MAbs...

Published: 7/25/2024 | Inventor(s): Robert Purcell, Suzanne Emerson, Zhaochun Chen

Keywords(s): Botulinum, DB3XXX, DBXXXX, DXXXXX, Hybridoma, Listed LPM Chang as of 4/15/2015, mabs, Neurotoxin, Neutralizing, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, UA1XXX, VJXXXX, WAXXXX, WIXXXX, XAXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, ResearchProducts > Antibodies